Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation

被引:20
作者
Berglund, Sofia [1 ,2 ]
Le Blanc, Katarina [2 ,4 ]
Remberger, Mats [2 ]
Gertow, Jens [2 ]
Uzunel, Mehmet [2 ]
Svenberg, Petter [1 ,2 ]
Winiarski, Jacek [3 ]
Ljungman, Per [4 ]
Ringden, Olle [1 ,2 ]
Uhlin, Michael [2 ]
Mattsson, Jonas [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Immunol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Pediat, Stockholm, Sweden
[4] Karolinska Univ Hosp, Karolinska Inst, Dept Haematol, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Umbilical cord blood transplantation; HSCT; Chimerism; MESENCHYMAL STEM-CELLS; VERSUS-HOST-DISEASE; IMMUNE RECONSTITUTION; HEMORRHAGIC CYSTITIS; PEDIATRIC-PATIENTS; MIXED CHIMERISM; STROMAL CELLS; SINGLE-CENTER; GRAFT; DONOR;
D O I
10.1097/TP.0b013e31826c39b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Umbilical cord blood transplantation (UCBT) is increasingly used and produces similar results to matched unrelated donor transplantation. Methods. We performed a retrospective single-center analysis of 50 umbilical cord blood transplantations UCBTs performed from 2001 to 2010, including 37 single and 13 double umbilical cord blood transplantations UCBTs. Results. The rate of engraftment of neutrophils was 88% at a median time of 29 days (range, 3-79). Complete donor chimerism (DC) within the CD19(+), CD3(+), and CD33(+) cell lineages was seen in 74%, 72%, and 76% of the patients, respectively. DC was associated with acute graft-versus-host disease (GVHD) grades II to IV for the CD3(+) cell lineage (P=0.01) and, in multivariate analysis, with total body irradiation for all lineages (P<0.01). Overall survival (OS) at 1 and 5 years was 55% and 43%. Nonmalignant diseases were associated with better 5-year OS (72%) than malignancies (28%; P=0.026). In multivariate analysis, a negative correlation was seen between OS and age (hazard ratio [HR], 1.04; 95% confidence interval [95% CI], 1.02-1.06; P<0.001), acute GVHD grades III and IV (HR, 3.43; 95% CI, 1.95-6.02; P<0.001), and mesenchymal stem cell treatment (HR, 2.66; 95% CI, 1.11-6.35; P=0.027). Transplant-related mortality at 100 days and 1 year was 16% and 30%. The incidence of acute GVHD grades II to IV was 34%. Acute GVHD grades III and IV was associated with ABO incompatibility (HR, 2.61; P=0.05) and myeloablative conditioning (HR, 4.17; P=0.047). Conclusions. The outcome in patients with nonmalignant diseases was acceptable, but transplant-related mortality in the whole group remains high. A significantly higher rate of DC was associated with total body irradiation-based conditioning and with acute GVHD grades II and IV.
引用
收藏
页码:1066 / 1074
页数:9
相关论文
共 44 条
[1]   On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS) [J].
Abdel-Rehim, M ;
Hassan, Z ;
Blomberg, L ;
Hassan, M .
THERAPEUTIC DRUG MONITORING, 2003, 25 (03) :400-406
[2]   Double unrelated reduced-intensity umbilical cord blood transplantation in adults [J].
Ballen, Karen K. ;
Spitzer, Thomas R. ;
Yeap, Beow Y. ;
McAfee, Steven ;
Dey, Bimalangshu R. ;
Attar, Eyal ;
Haspel, Richard ;
Kao, Grace ;
Liney, Deborah ;
Alyea, Edwin ;
Lee, Stephanie ;
Cutler, Corey ;
Ho, Vincent ;
Soiffer, Robert ;
Antin, Joseph H. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) :82-89
[3]   Optimizing Unrelated Donor Cord Blood Transplantation [J].
Barker, Juliet N. ;
Rocha, Vanderson ;
Scaradavou, Andromachi .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (01) :154-161
[4]   Stable mixed donor-donor chimerism after double cord blood transplantation [J].
Berglund, Sofia ;
Okas, Mantas ;
Gertow, Jens ;
Uhlin, Michael ;
Mattsson, Jonas .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (04) :526-531
[5]   Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation [J].
Bernardo, M. E. ;
Ball, L. M. ;
Cometa, A. M. ;
Roelofs, H. ;
Zecca, M. ;
Avanzini, M. A. ;
Bertaina, A. ;
Vinti, L. ;
Lankester, A. ;
Maccario, R. ;
Ringden, O. ;
Le Blanc, K. ;
Egeler, R. M. ;
Fibbe, W. E. ;
Locatelli, F. .
BONE MARROW TRANSPLANTATION, 2011, 46 (02) :200-207
[6]   Expanding the role of umbilical cord blood transplantation [J].
Brunstein, Claudio G. ;
Setubal, Daniela C. ;
Wagner, John E. .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (01) :20-35
[7]   Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution [J].
Escalon, Maricer P. ;
Komanduri, Krishna V. .
CURRENT OPINION IN ONCOLOGY, 2010, 22 (02) :122-129
[8]   Immune reconstitution following hematopoietic stem-cell transplantation [J].
Geddes, Michelle ;
Storek, Jan .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (02) :329-348
[9]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[10]   Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults [J].
Gonzalo-Daganzo, Rosa ;
Regidor, Carmen ;
Martin-Donaire, Trinidad ;
Angel Rico, Miguel ;
Bautista, Guiomar ;
Krsnik, Isabel ;
Fores, Rafael ;
Ojeda, Emilio ;
Sanjuan, Isabel ;
Garcia-Marco, Jose A. ;
Navarro, Belen ;
Gil, Santiago ;
Sanchez, Rocio ;
Panadero, Nuria ;
Gutierrez, Yolanda ;
Garcia-Berciano, Miguel ;
Perez, Nuria ;
Millan, Isabel ;
Cabrera, Rafael ;
Fernandez, Manuel N. .
CYTOTHERAPY, 2009, 11 (03) :278-288